Draupnir’s novel SORTAC platform expands reach of targeted protein degradation to extracellular proteins, demonstrating in vitro and in vivo efficacy against…
SHANGHAI, March 30, 2026 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization…